CDC's 2019 AR Investment Map

Click left or right to see more factsheets.

Explore Investments & Activities

Local health department that received additional funding.
Location of one of seven AR Laboratory Network regional labs.
Location of the National Tuberculosis Molecular Surveillance Center.
Global PDF Preview

This map represents CDC’s largest funding categories for antibiotic resistance. It shows extramural funding that supports AR activities from multiple funding lines.

Investing to Protect the United States and World against Antibiotic Resistance
Antibiotic resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance.

The AR Investment Map showcases CDC’s critical activities in the United States and abroad to combat antibiotic resistance with investments in laboratory and epidemiological expertise and public health innovation.

CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.
Strategy PDF Preview

Since 2016

U.S. and 19+ Countries Abroad

$300 million
to 59 state and local health departments

local AR experts

AR Lab Network detects a resistant germ that requires investigation every
4 hours

Whole genome sequencing on 116,000+ germ samples

Detection, Response & Containment

   Laboratory & Diagnostics: Gold-standard lab capacity offered to all U.S. state and regional labs through CDC’s AR Laboratory Network, and on-the-ground lab expertise and assistance in some countries abroad

   Epidemiology Capacity for Response: Increased capacity in state and local health departments and some countries for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread


   Surveillance & Science: More effective tracking and prevention of healthcare-associated infections, foodborne illness, and gonorrhea

   Improved Antibiotic Use: Improving antibiotic use to ensure antibiotics are available and work to protect people from life-threatening infections or sepsis


   Insights for Practice: Innovations and collaborations with academic and healthcare partners to identify and implement new ways to prevent antibiotic-resistant infections and their spread in the U.S. and abroad

   Research and Development: Sharing isolates that inform development of new drugs and diagnostics, and making public CDC’s sequencing data from AR pathogens to spur innovation in industry

Antibiotic Resistance Investments - Version